Skip to main content
TipRanks
Go Ultimate75% OFF

Medpace Holdings (MEDP) Drug Pipeline

1 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
[68Ga]Bed003Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (Pdac), Epithelial Ovarian Cancer, Invasive Lobular Breast Carcinoma, Gastric Cancer (Gc)Phase IIRecruiting[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsJun 30, 2026
Sham Procedure, RugonersenAngelman SyndromePhase IIIRecruitingBEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.May 15, 2026
[18F]FpyqcpColorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma, Invasive Lobular Breast Carcinomaphase1AndPhase2Recruiting[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsFeb 10, 2026
177Lu-BetabartCervical Cancer, Ovarian Cancer, Colorectal Cancer, Castration-Resistant Prostate Cancer (Crpc), Endometrial Cancer, Esophageal Squamous Cell Carcinoma (Escc), Nsclc (Non-Small Cell Lung Cancer), Tnbc, Triple Negative Breast Cancer, Small Cell Lung Cancer (Sclc ), Head &Amp; Neck Squamous Cell Carcinoma (Hnscc)phase1AndPhase2Recruiting177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsSep 11, 2025
177Lu-Tlx250Ccrcc, Renal Cell Carcinoma (Rcc), Renal Cell Carcinoma (Kidney Cancer), Renal Cell Cancer Metastatic, Renal Cell Cancer, Recurrent, Clear Cell Renal Cell Cancer (Ccrcc)Phase IIINot Yet RecruitingStudy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCCAug 18, 2025
Lerodalcibep 300 Mg Monthly ScFamilial Hypercholesterolemia - HeterozygousPhase IIIEnrolling By InvitationStudy to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FHJul 28, 2025
Rad101Brain Metastases From Solid TumorsPhase IIActive Not RecruitingPhase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain MetastasesDec 19, 2024
Lutetium Rhpsma 10.1 And PluvictoMetastatic Prostate CancerearlyPhase1TerminatedA Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate CancerJun 17, 2024―
SevasemtenBecker Muscular DystrophyPhase IIEnrolling By InvitationOpen-Label Extension of EDG-5506 in Participants With Becker Muscular DystrophySep 27, 2023
AzeliragonGlioblastomaPhase IIActive Not RecruitingAzeliragon in MGMT Unmethylated GlioblastomaAug 03, 2023―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Medpace Holdings Inc (MX:MEDP) have in its pipeline
Medpace Holdings MX:MEDP is currently developing the following drugs: [68Ga]Bed003, Sham Procedure, Rugonersen, [18F]Fpyqcp, 177Lu-Betabart, 177Lu-Tlx250, Lerodalcibep 300 Mg Monthly Sc, Rad101, Lutetium Rhpsma 10.1 And Pluvicto, Sevasemten, Azeliragon, Tnx-103, Chs-006, Toripalimab, Sevasemten 10 Mg, Sevasemten 5 Mg, Sevasemten 12.5 Mg, Meropenem, Cefepime-Zidebactam, Avm0703, Avacopan, Investigator's Choice, Pritelivir, Men1703. These drug candidates are in various stages of clinical development as the company works toward FDA approval.